Lineage plasticity causes therapeutic resistance; however, it remains unclear how the fate conversion and phenotype switching of cancer-associated fibroblasts (CAFs) are implicated in disease relapse. Here, we show that androgen deprivation therapy (ADT)-induced SPP1+ myofibroblastic CAFs (myCAFs) are critical stromal constituents that drive the development of castration-resistant prostate cancer (CRPC). Our results reveal that SPP1+ myCAFs arise from the inflammatory CAFs in hormone-sensitive PCa; therefore, they represent two functional states of an otherwise ontogenically identical cell type. Antiandrogen treatment unleashes TGF-β signaling, resulting in SOX4-SWI/SNF-dependent CAF phenotype switching. SPP1+ myCAFs in turn render PCa refractory to ADT via an SPP1-ERK paracrine mechanism. Importantly, these sub-myCAFs are associated with inferior therapeutic outcomes, providing the rationale for inhibiting polarization or paracrine mechanisms to circumvent castration resistance. Collectively, our results highlight that therapy-induced phenotypic switching of CAFs is coupled with disease progression and that targeting this stromal component may restrain CRPC.
Pubmed ID: 37352863 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets Cytokeratin 8
View all literature mentionsThis monoclonal targets Androgen Receptor antibody [ER179(2)]
View all literature mentionsThis monoclonal targets RSK1 p90 (phospho S380)
View all literature mentionsThis polyclonal targets H3K27ac
View all literature mentionsThis recombinant monoclonal targets Collagen I
View all literature mentionsThis polyclonal targets Mouse Osteopontin (OPN) Affinity Purified Ab
View all literature mentionsThis monoclonal targets TGF-β
View all literature mentionsThis polyclonal targets TGFBR2
View all literature mentionsThis unknown targets TGF-beta Receptor I
View all literature mentionsThis monoclonal targets ARID1A/BAF250A
View all literature mentionsThis monoclonal targets SMARCC1
View all literature mentionsThis monoclonal targets ERBB3
View all literature mentionsThis monoclonal targets RSK1 p90
View all literature mentionsThis monoclonal targets Erbb3
View all literature mentionsThis monoclonal targets Phospho-Akt (Thr308) (244F9) Rabbit mAb
View all literature mentionsThis monoclonal targets Akt (pan) (C67E7) Rabbit mAb
View all literature mentionsThis monoclonal targets Phospho-Akt (Ser473)
View all literature mentionsThis polyclonal targets p44/42 MAPK (Erk1/2)
View all literature mentionsThis monoclonal targets Phospho-Smad3 (Ser423/425) (C25A9) Rabbit mAb
View all literature mentionsThis monoclonal targets SMAD2
View all literature mentionsThis polyclonal targets Phospho-Smad2 (Ser465/467)
View all literature mentionsThis polyclonal targets Smad3
View all literature mentionsThis monoclonal targets Smad2 (D43B4) XP Rabbit mAb
View all literature mentionsThis monoclonal targets C4A
View all literature mentionsThis monoclonal targets Beta Actin
View all literature mentionsThis monoclonal targets p53 (1C12) Mouse mAb
View all literature mentionsThis monoclonal targets PTEN
View all literature mentionsThis monoclonal targets HB-EGF (H-1)
View all literature mentionsThis monoclonal targets VEGF-C (E-6)
View all literature mentionsThis monoclonal targets Podoplanin
View all literature mentionsThis monoclonal targets CD29
View all literature mentionsThis monoclonal targets CD90.2
View all literature mentionsThis monoclonal targets CD90.2 (Thy-1.2)
View all literature mentionsThis monoclonal targets CD326
View all literature mentionsThis monoclonal targets CD31 (PECAM-1)
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets DYKDDDDK Tag
View all literature mentionsThis monoclonal targets BRG1 antibody [EPNCIR111A]
View all literature mentionsThis monoclonal targets Actin, α-Smooth Muscle
View all literature mentionsThis monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)
View all literature mentionsThis monoclonal targets Ki-67
View all literature mentionsThis polyclonal targets TGF Beta 1
View all literature mentionsThis monoclonal targets CD140a (PDGFRA)
View all literature mentionsThis monoclonal targets PDGF Receptor alpha
View all literature mentionsThis monoclonal targets COL1A1
View all literature mentionsThis monoclonal targets Spp1
View all literature mentionsThis monoclonal targets OPN (AKm2A1)
View all literature mentionsThis monoclonal targets PTN
View all literature mentionsCell line Myc-CaP is a Cancer cell line with a species of origin Mus musculus
View all literature mentionsCell line LNCaP C4-2 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsCell line LAPC-4 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsCell line PC-3 is a Cancer cell line with a species of origin Homo sapiens (Human)
View all literature mentionsCell line HEK293T/17 is a Transformed cell line with a species of origin Homo sapiens (Human)
View all literature mentions